Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
With today’s announcement of the transaction completion, Grifols and Haier Group will work together through Shanghai RAAS (SRAAS) to drive...
Day: June 18, 2024
Vyluma Meets with FDA on Atropine Sulfate Ophthalmic Solution 0.01% Under Development to Treat Pediatric Myopia
Vyluma Discusses Response to FDA’s Questions and Clarifies Regulatory Pathway for its 505(b)(2) NDABRIDGEWATER, N.J., June 18, 2024 (GLOBE NEWSWIRE)...
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions
GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced oral presentations...
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
CELEBRATION, Fla. and ELK GROVE VILLAGE, Ill., June 18, 2024 (GLOBE NEWSWIRE) -- Orsini Specialty Pharmacy (Orsini), and Zevra Therapeutics,...
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living...
Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome
Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and...
Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Small Molecule Therapeutics for Immunological Diseases
Collaboration will leverage Belharra’s proprietary, non-covalent chemoproteomics platform to identify and advance small molecules against Sanofi-designated immunology targetsSanofi to lead...
EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and...
Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting
Survival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline...
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented...
LSL Pharma Group Completes the Acquisition of Virage Santé
BOUCHERVILLE, Québec, June 18, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL) ("the Company" or "LSL Pharma"), a...
Silk Road Medical Announces Definitive Agreement to be Acquired by Boston Scientific
Boston Scientific to acquire Silk Road Medical for $27.50 per share in cash SUNNYVALE, Calif., June 18, 2024 (GLOBE NEWSWIRE)...
PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial
After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID...
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
—Proteomic Analysis of Patient Samples Further Confirms that CCL24 is Associated with Primary Sclerosing Cholangitis (PSC) Severity and Progression, Highlighting...
Emergex Announces MHRA Approval of MIA (IMP) Manufacturing and Import Authorisation License
ABINGDON, United Kingdom, June 18, 2024 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company...
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease...
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of...
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges
$10 million funding round from U.S. and EU strategic investors, will accelerate growth and empower efficient cultivated meat, fish and...
Future Health Index 2024 global report: Healthcare leaders turn to AI to address critical gaps in patient care
A clinician in consultation with a patient A clinician in discussion with a young patient Future Health Index 2024 report...
Altus Formulation and Spektar Join Forces in New Specialty Company Spektus Pharma
New company develops value-added medicines in the CNS space for global partneringMONTREAL and DUBAI, United Arab Emirates, June 18, 2024...